PPG Industries Inc
Change company Symbol lookup
Select an option...
PPG PPG Industries Inc
DUK Duke Energy Corp
CSCO Cisco Systems Inc
HMNF HMN Financial Inc
BAM Brookfield Asset Management Inc
XOM Exxon Mobil Corp
NEWR New Relic Inc
T AT&T Inc
AICAF Air China Ltd
MMM 3M Co
Go

Materials : Chemicals | Large Cap Value
Company profile

PPG Industries, Inc. manufactures and distributes a range of coatings and specialty materials. The Company has two segments: Performance Coatings and Industrial Coatings. The Performance Coatings segment includes the refinish, aerospace, protective and marine, architectural businesses. The Industrial Coatings segment includes the automotive original equipment manufacturer (OEM), industrial coatings, packaging coatings, coatings services and specialty coatings and materials businesses. The Company's geographical segments include the United States, Canada, Western Europe, Latin America, Central and Eastern Europe, the Middle East, Africa and Asia Pacific. The Company's brands include PPG, GLIDDEN, COMEX, OLYMPIC, DULUX, SIKKENS, PPG PITTSBURGH PAINTS, MULCO, FLOOD, LIQUID NAILS, SICO, CIL, RENNER, TAUBMANS, WHITE KNIGHT, BRISTOL, HOMAX, DEKORAL, TRILAK, GORI, and BONDEX, among others.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$120.33
Day's Change
-1.41 (-1.16%)
Bid
--
Ask
--
B/A Size
--
Day's High
122.77
Day's Low
120.29
Volume
(Light)
Volume:
688,578

10-day average volume:
1,272,320
688,578

Regeneron's stock gains on $450 million manufacturing deal with U.S. for experimental COVID-19 treatment

7:22 am ET July 7, 2020 (MarketWatch)
Print

Shares of Regeneron Pharmaceuticals Inc. (REGN) gained 0.9% in premarket trading on Tuesday after the drugmaker said it received $450 million from the federal government to manufacture and supply its still investigational COVID-19 treatment. The agreement is with the Biomedical Advanced Research and Development Authority and the Department of Defense. Regeneron said Monday (http://www.marketwatch.com/story/regeneron-shares-gain-as-the-company-launches-phase-3-trial-for-covid-19-antibody-treatment-2020-07-06) that the antibody cocktail candidate is being testing in two Phase 2/3 clinical studies as a treatment for COVID-19; the therapy is also in a Phase 3 trial evaluating whether or not it can prevent someone who has been exposed by a close contact from getting infected with the virus. The company said that if the Food and Drug Administration grants the experimental therapy an emergency use authorization or an approval, "the government has committed to making doses from these lots available to the American people at no cost and would be responsible for their distribution." Regeneron's stock has soared 67.0% since the start of the year, compared with the S&P 500 , which is down 1.5%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 07, 2020 07:22 ET (11:22 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.